|
Mar 3
|
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
|
|
Mar 1
|
Personalis Full Year 2024 Earnings: Beats Expectations
|
|
Feb 28
|
Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
|
|
Feb 27
|
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Personalis: Q4 Earnings Snapshot
|
|
Feb 27
|
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 20
|
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 18
|
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
|
|
Feb 13
|
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
|
|
Jul 24
|
Personalis to Announce Second Quarter 2024 Financial Results
|
|
Jun 18
|
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
|
|
Jun 4
|
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
|
|
May 31
|
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
|
|
May 22
|
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
|
|
May 9
|
Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?
|
|
May 9
|
Personalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)
|
|
May 9
|
Q1 2024 Personalis Inc Earnings Call
|
|
May 9
|
Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...
|
|
May 8
|
Personalis Reports First Quarter 2024 Financial Results
|